Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Phase 1 Trial of Concurrent Gemcitabine and Cisplatin with Image Guided Intensity Modulated Radiation Therapy for Locoregionally Advanced Cervical Carcinoma

International Journal of Radiation Oncology*Biology*Physics(2020)10.1016/j.ijrobp.2020.04.019Source: DataRank Database

Phase 1 Trial of Concurrent Gemcitabine and Cisplatin with Image Guided Intensity Modulated Radiation Therapy for Locoregionally Advanced Cervical Carcinoma is a research paper published in International Journal of Radiation Oncology*Biology*Physics (2020). On theSindex it has a DataRank of 0.909. It has been cited 18 times, with 11 citing works in its 1-hop citation network.

N/A

0.909DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access18 citations · 11 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT01554410

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 1.47)OA: greenTopics (114)Linked Datasets (4)DataCite Reuse (4)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 49%Citation Network 51%

Base Score Contribution

0.442

From this paper's citation signal

Citation Network Contribution

0.468

From 7 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 11 citers.

Correlation between changes of pelvic bone marrow fat content and hematological toxicity in concurrent chemoradiotherapy for cervical cancer
Radiation Oncology202219 citations24 referencesContributes 0.125
In Regard to Mell et al
International Journal of Radiation Oncology*Biology*Physics20201 citations8 referencesContributes 0.087
Role of 18FDG PET/CT metabolic parameters in predicting hematological toxicity during chemoradiotherapy for locally advanced cervical cancer
Frontiers in Oncology20223 citations17 referencesContributes 0.082
Functional MRI radiomics-based assessment of pelvic bone marrow changes after concurrent chemoradiotherapy for cervical cancer
BMC Cancer202211 citations32 referencesContributes 0.078
Comparison of treatment outcomes of surgery and radiotherapy, including concurrent chemoradiotherapy for stage Ib2-IIb cervical adenocarcinoma patients: a retrospective study
Journal of Gynecologic Oncology20218 citations30 referencesContributes 0.073

Authors (14)

Ronghui Xu ORCID,Catheryn M. Yashar ORCID,Michael McHale ORCID,John Einck ORCID,Jyoti Mayadev ORCID

Live enrichment

PubMed:32334034 PMC:PMC9440640 OpenAlex:https://openalex.org/W3018122338

National Institutes of Health

Grant: UL1TR001442

American Cancer Society

Grant: IRG-70-002

National Institutes of Health

Grant: 2UL1TR001442-06

UC San Diego Clinical and Translational Research Institute

FWCI

1.47

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9440640

publisherhttps://api.elsevier.com/content/article/PII:S0360301620310373?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0360301620310373?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ijrobp.2020.04.019

Fields of Study

Endometrial and Cervical Cancer TreatmentsColorectal and Anal CarcinomasOvarian cancer diagnosis and treatment0302 clinical medicine03 medical and health sciencesAdultAgedCisplatinCombined Modality TherapyDeoxycytidineFemaleHumansMiddle AgedRadiotherapy, Image-GuidedRadiotherapy, Intensity-ModulatedTreatment OutcomeUterine Cervical NeoplasmsYoung AdultGemcitabine

MeSH Terms

GemcitabineAdultAgedUterine Cervical NeoplasmsCisplatinCombined Modality TherapyDeoxycytidineFemaleHumansMiddle AgedTreatment OutcomeRadiotherapy, Intensity-ModulatedYoung AdultRadiotherapy, Image-Guided

Keywords

MedicineGemcitabineCervical cancerRadiation therapyClinical endpointCisplatinCervixRegimenChemoradiotherapyNuclear medicineCancerOncologyInternal medicineUrologyChemotherapyRadiologyClinical trialWomen's Health (rcdc)Radiation Oncology (rcdc)Intensity-Modulated (mesh)Uterine Cervical NeoplasmsDeoxycytidineClinical Research (rcdc)5105 Medical and biological physics (for-2020)6.5 Radiotherapy and other non-invasive therapies (hrcs-rac)Theoretical and computational chemistryIntensity-Modulated1103 Clinical Sciences (for)32 Biomedical and Clinical Sciences (for-2020)Cancer (rcdc)Humans (mesh)Young Adult (mesh)0299 Other Physical Sciences (for)Treatment Outcome (mesh)Gemcitabine (mesh)1112 Oncology and Carcinogenesis (for)Middle AgedCervical Cancer (rcdc)Combined Modality Therapy6.5 Radiotherapy and other non-invasive therapiesOther Physical SciencesImage-Guided (mesh)Treatment OutcomeImage-Guided6.1 PharmaceuticalsFemaleDigestive Diseases (rcdc)AdultClinical SciencesOncology and CarcinogenesisClinical Trials and Supportive ActivitiesClinical Trials and Supportive Activities (rcdc)610Uterine Cervical Neoplasms (mesh)Young AdultClinical Research616Middle Aged (mesh)3211 Oncology and carcinogenesis (for-2020)HumansOncology & Carcinogenesis3202 Clinical Sciences (for-2020)Cisplatin (mesh)Combined Modality Therapy (mesh)AgedMedical and biological physics6.1 Pharmaceuticals (hrcs-rac)Biomedical and Clinical SciencesRadiotherapyAged (mesh)Cancer (hrcs-hc)Oncology & Carcinogenesis (science-metrix)Female (mesh)Radiation OncologyAdult (mesh)3407 Theoretical and computational chemistry (for-2020)Women's HealthRadiotherapy, Intensity-ModulatedDigestive DiseasesDeoxycytidine (mesh)Radiotherapy, Image-Guided

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Functional MRI radiomics-based assessment of pelvic bone marrow changes after concurrent chemoradiotherapy for cervical cancer

10.6084/m9.figshare.21522154.v1figshare

Additional file 1 of Functional MRI radiomics-based assessment of pelvic bone marrow changes after concurrent chemoradiotherapy for cervical cancer

10.6084/m9.figshare.21522154figshare

Additional file 1 of Dosimetric evaluation of bone marrow sparing in proton radiotherapy for cervical cancer guided by MR functional imaging

10.6084/m9.figshare.22609414.v1figshare

Additional file 1 of Dosimetric evaluation of bone marrow sparing in proton radiotherapy for cervical cancer guided by MR functional imaging

10.6084/m9.figshare.22609414figshare

Phase 1 Trial of Concurrent Gemcitabine and Cisplatin with Image Guided Intensity Modulated Radiation Therapy for Locoregionally Advanced Cervical Carcinoma

FAIR Checklist

DataRank Breakdown

Top 5 citers driving the network score

Authors (14)

Funding (3 grants)

Impact

Open Access

Topics

Linked Datasets (4)

Annotations (Europe PMC)